Eintrag weiter verarbeiten
Blood alterations preceding clinical manifestation of glioblastoma.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Journal of Clinical Oncology, 30, 2012, 15_suppl, S. 2024-2024 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Ilhan-Mutlu, Aysegul Wagner, Ludwig Woehrer, Adelheid Susanne, Jungwirth Marosi, Christine Fischer, Peter Preusser, Matthias Ilhan-Mutlu, Aysegul Wagner, Ludwig Woehrer, Adelheid Susanne, Jungwirth Marosi, Christine Fischer, Peter Preusser, Matthias |
|---|---|
| author |
Ilhan-Mutlu, Aysegul Wagner, Ludwig Woehrer, Adelheid Susanne, Jungwirth Marosi, Christine Fischer, Peter Preusser, Matthias |
| spellingShingle |
Ilhan-Mutlu, Aysegul Wagner, Ludwig Woehrer, Adelheid Susanne, Jungwirth Marosi, Christine Fischer, Peter Preusser, Matthias Journal of Clinical Oncology Blood alterations preceding clinical manifestation of glioblastoma. Cancer Research Oncology |
| author_sort |
ilhan-mutlu, aysegul |
| spelling |
Ilhan-Mutlu, Aysegul Wagner, Ludwig Woehrer, Adelheid Susanne, Jungwirth Marosi, Christine Fischer, Peter Preusser, Matthias 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2024 <jats:p> 2024 </jats:p><jats:p> Background: Glioblastoma is the most common and aggressive primary brain tumour in adults. There is lack of knowledge on biochemical blood alterations prior to clinical diagnosis of glioblastoma. We had the rare opportunity to investigate selected blood markers from plasma samples taken 12, 42 and 72 months before tumor manifestation in a glioblastoma patient. This index patient was enrolled in the longitudinal population based Vienna Transdanube Aging Study (VITA), which prospectively collects blood plasma from 600 participants at baseline (age 75), 30 and 60 months thereafter. Methods: We determined plasma levels of S100B, neuropeptide Y (NPY), secretagogin (SCGN), microRNA-21, microRNA-let7, microRNA-128, and microRNA-342-3p in all three blood samples from our index patient and in consecutive blood samples from five male and five female controls from the VITA cohort. These proteins and microRNAs were previously shown to be relevant for the pathobiology of glioblastomas. None of the controls had a malignant or neurological disease. Protein markers were analysed using commercially available ELISAs and microRNAs were quantified using RT-qPCR. Results: Compared to baseline values, we found a significant increase of microRNA-21 (up to 4-fold) and microRNA-let7 (up to 7-fold) levels in the blood samples of our index patient, whereas control samples showed almost stable levels of these markers. There was no significant difference in S100B, NPY, SCGN, microRNA-128, and microRNA-342-3p plasma levels between the index patient and controls. Conclusions: Increases of microRNA-21 and microRNA-let7 plasma levels may be associated with pre-clinical development of glioblastoma. </jats:p> Blood alterations preceding clinical manifestation of glioblastoma. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2012.30.15_suppl.2024 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4yMDI0 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4yMDI0 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2012 |
| issn |
1527-7755 0732-183X |
| issn_str_mv |
1527-7755 0732-183X |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
ilhanmutlu2012bloodalterationsprecedingclinicalmanifestationofglioblastoma |
| publishDateSort |
2012 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Blood alterations preceding clinical manifestation of glioblastoma. |
| title_unstemmed |
Blood alterations preceding clinical manifestation of glioblastoma. |
| title_full |
Blood alterations preceding clinical manifestation of glioblastoma. |
| title_fullStr |
Blood alterations preceding clinical manifestation of glioblastoma. |
| title_full_unstemmed |
Blood alterations preceding clinical manifestation of glioblastoma. |
| title_short |
Blood alterations preceding clinical manifestation of glioblastoma. |
| title_sort |
blood alterations preceding clinical manifestation of glioblastoma. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2024 |
| publishDate |
2012 |
| physical |
2024-2024 |
| description |
<jats:p> 2024 </jats:p><jats:p> Background: Glioblastoma is the most common and aggressive primary brain tumour in adults. There is lack of knowledge on biochemical blood alterations prior to clinical diagnosis of glioblastoma. We had the rare opportunity to investigate selected blood markers from plasma samples taken 12, 42 and 72 months before tumor manifestation in a glioblastoma patient. This index patient was enrolled in the longitudinal population based Vienna Transdanube Aging Study (VITA), which prospectively collects blood plasma from 600 participants at baseline (age 75), 30 and 60 months thereafter. Methods: We determined plasma levels of S100B, neuropeptide Y (NPY), secretagogin (SCGN), microRNA-21, microRNA-let7, microRNA-128, and microRNA-342-3p in all three blood samples from our index patient and in consecutive blood samples from five male and five female controls from the VITA cohort. These proteins and microRNAs were previously shown to be relevant for the pathobiology of glioblastomas. None of the controls had a malignant or neurological disease. Protein markers were analysed using commercially available ELISAs and microRNAs were quantified using RT-qPCR. Results: Compared to baseline values, we found a significant increase of microRNA-21 (up to 4-fold) and microRNA-let7 (up to 7-fold) levels in the blood samples of our index patient, whereas control samples showed almost stable levels of these markers. There was no significant difference in S100B, NPY, SCGN, microRNA-128, and microRNA-342-3p plasma levels between the index patient and controls. Conclusions: Increases of microRNA-21 and microRNA-let7 plasma levels may be associated with pre-clinical development of glioblastoma. </jats:p> |
| container_issue |
15_suppl |
| container_start_page |
2024 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
30 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792321116205744135 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T10:56:52.437Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Blood+alterations+preceding+clinical+manifestation+of+glioblastoma.&rft.date=2012-05-20&genre=article&issn=1527-7755&volume=30&issue=15_suppl&spage=2024&epage=2024&pages=2024-2024&jtitle=Journal+of+Clinical+Oncology&atitle=Blood+alterations+preceding+clinical+manifestation+of+glioblastoma.&aulast=Preusser&aufirst=Matthias&rft_id=info%3Adoi%2F10.1200%2Fjco.2012.30.15_suppl.2024&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792321116205744135 |
| author | Ilhan-Mutlu, Aysegul, Wagner, Ludwig, Woehrer, Adelheid, Susanne, Jungwirth, Marosi, Christine, Fischer, Peter, Preusser, Matthias |
| author_facet | Ilhan-Mutlu, Aysegul, Wagner, Ludwig, Woehrer, Adelheid, Susanne, Jungwirth, Marosi, Christine, Fischer, Peter, Preusser, Matthias, Ilhan-Mutlu, Aysegul, Wagner, Ludwig, Woehrer, Adelheid, Susanne, Jungwirth, Marosi, Christine, Fischer, Peter, Preusser, Matthias |
| author_sort | ilhan-mutlu, aysegul |
| container_issue | 15_suppl |
| container_start_page | 2024 |
| container_title | Journal of Clinical Oncology |
| container_volume | 30 |
| description | <jats:p> 2024 </jats:p><jats:p> Background: Glioblastoma is the most common and aggressive primary brain tumour in adults. There is lack of knowledge on biochemical blood alterations prior to clinical diagnosis of glioblastoma. We had the rare opportunity to investigate selected blood markers from plasma samples taken 12, 42 and 72 months before tumor manifestation in a glioblastoma patient. This index patient was enrolled in the longitudinal population based Vienna Transdanube Aging Study (VITA), which prospectively collects blood plasma from 600 participants at baseline (age 75), 30 and 60 months thereafter. Methods: We determined plasma levels of S100B, neuropeptide Y (NPY), secretagogin (SCGN), microRNA-21, microRNA-let7, microRNA-128, and microRNA-342-3p in all three blood samples from our index patient and in consecutive blood samples from five male and five female controls from the VITA cohort. These proteins and microRNAs were previously shown to be relevant for the pathobiology of glioblastomas. None of the controls had a malignant or neurological disease. Protein markers were analysed using commercially available ELISAs and microRNAs were quantified using RT-qPCR. Results: Compared to baseline values, we found a significant increase of microRNA-21 (up to 4-fold) and microRNA-let7 (up to 7-fold) levels in the blood samples of our index patient, whereas control samples showed almost stable levels of these markers. There was no significant difference in S100B, NPY, SCGN, microRNA-128, and microRNA-342-3p plasma levels between the index patient and controls. Conclusions: Increases of microRNA-21 and microRNA-let7 plasma levels may be associated with pre-clinical development of glioblastoma. </jats:p> |
| doi_str_mv | 10.1200/jco.2012.30.15_suppl.2024 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4yMDI0 |
| imprint | American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2012 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229 |
| issn | 1527-7755, 0732-183X |
| issn_str_mv | 1527-7755, 0732-183X |
| language | English |
| last_indexed | 2024-03-01T10:56:52.437Z |
| match_str | ilhanmutlu2012bloodalterationsprecedingclinicalmanifestationofglioblastoma |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 2024-2024 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Ilhan-Mutlu, Aysegul Wagner, Ludwig Woehrer, Adelheid Susanne, Jungwirth Marosi, Christine Fischer, Peter Preusser, Matthias 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2024 <jats:p> 2024 </jats:p><jats:p> Background: Glioblastoma is the most common and aggressive primary brain tumour in adults. There is lack of knowledge on biochemical blood alterations prior to clinical diagnosis of glioblastoma. We had the rare opportunity to investigate selected blood markers from plasma samples taken 12, 42 and 72 months before tumor manifestation in a glioblastoma patient. This index patient was enrolled in the longitudinal population based Vienna Transdanube Aging Study (VITA), which prospectively collects blood plasma from 600 participants at baseline (age 75), 30 and 60 months thereafter. Methods: We determined plasma levels of S100B, neuropeptide Y (NPY), secretagogin (SCGN), microRNA-21, microRNA-let7, microRNA-128, and microRNA-342-3p in all three blood samples from our index patient and in consecutive blood samples from five male and five female controls from the VITA cohort. These proteins and microRNAs were previously shown to be relevant for the pathobiology of glioblastomas. None of the controls had a malignant or neurological disease. Protein markers were analysed using commercially available ELISAs and microRNAs were quantified using RT-qPCR. Results: Compared to baseline values, we found a significant increase of microRNA-21 (up to 4-fold) and microRNA-let7 (up to 7-fold) levels in the blood samples of our index patient, whereas control samples showed almost stable levels of these markers. There was no significant difference in S100B, NPY, SCGN, microRNA-128, and microRNA-342-3p plasma levels between the index patient and controls. Conclusions: Increases of microRNA-21 and microRNA-let7 plasma levels may be associated with pre-clinical development of glioblastoma. </jats:p> Blood alterations preceding clinical manifestation of glioblastoma. Journal of Clinical Oncology |
| spellingShingle | Ilhan-Mutlu, Aysegul, Wagner, Ludwig, Woehrer, Adelheid, Susanne, Jungwirth, Marosi, Christine, Fischer, Peter, Preusser, Matthias, Journal of Clinical Oncology, Blood alterations preceding clinical manifestation of glioblastoma., Cancer Research, Oncology |
| title | Blood alterations preceding clinical manifestation of glioblastoma. |
| title_full | Blood alterations preceding clinical manifestation of glioblastoma. |
| title_fullStr | Blood alterations preceding clinical manifestation of glioblastoma. |
| title_full_unstemmed | Blood alterations preceding clinical manifestation of glioblastoma. |
| title_short | Blood alterations preceding clinical manifestation of glioblastoma. |
| title_sort | blood alterations preceding clinical manifestation of glioblastoma. |
| title_unstemmed | Blood alterations preceding clinical manifestation of glioblastoma. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2024 |